Related Experiment Videos

Mannose-binding lectin gene polymorphism and risk factors for cardiovascular disease in postmenopausal women

Claudio Lera Orsatti1, Eliana Aguiar Petri Nahás1, Jorge Nahas-Neto1

  • 1Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University- UNESP, Botucatu, São Paulo, Brazil.

Molecular Immunology
|May 28, 2014
PubMed

Insights

Genetic variations in Mannose-binding lectin (MBL2) may influence cardiovascular disease (CVD) risk in postmenopausal women. Polymorphism at codon 54 is linked to reduced hypertension and insulin resistance, key CVD risk factors.

Area of Science:

  • Immunogenetics
  • Cardiovascular Disease Epidemiology
  • Menopause Research

Background:

  • Postmenopausal women exhibit altered inflammatory responses, increasing cardiovascular disease (CVD) susceptibility.
  • Genetic factors play a role in CVD risk.
  • Mannose-binding lectin (MBL), part of the innate immune system, activates complement cascade.

Purpose of the Study:

  • To investigate the association between Mannose-binding lectin gene (MBL2) polymorphisms and cardiovascular risk factors in postmenopausal women.
  • To determine if MBL2 genetic variations influence hypertension and insulin resistance.

Main Methods:

  • Cross-sectional study of 311 Brazilian postmenopausal women (age ≥45).
  • Exclusion criteria included current CVD, diabetes, kidney disease, autoimmune diseases, and cancer.
  • MBL2 polymorphisms at codons 54 and 57 analyzed via PCR; cardiovascular risk factors assessed through clinical, anthropometric, and biochemical evaluations.

Main Results:

  • Codon 54 polymorphism present in 25.8% of women; codon 57 in 12.2%.
  • Codon 54 polymorphism significantly associated with lower odds of hypertension (OR 0.55) and insulin resistance (OR 0.46).
  • No significant association found between codon 57 polymorphism and CVD risk factors.

Conclusions:

  • MBL2 codon 54 polymorphism is associated with reduced risk of hypertension and insulin resistance in postmenopausal women.
  • These findings suggest a potential protective role of specific MBL2 variants against key cardiovascular risk factors.
Abstract

Keywords:
Cardiovascular diseaseMannose-binding lectinPolymorphismPostmenopausal women

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K